All Activity

San Francisco officials are seeking public input on newly released draft rules for cannabis cafes in line with a California state law enacted last year that authorizes local governments to let marijuana retailers to expand their services. In July, the city’s Board of Supervisors and mayor approved an ordinance to let marijuana dispensaries serve food and drinks inside their on-site consumption areas. On Friday, the city’s Office of Cannabis posted proposed regulations for how those cannabis cafes will operate. The draft rules touch on operations plans, employee training, security, deliveries, inventory control and access for medical cannabis patients. Public feedback is being accepted through September 25. In late 2024, Gov. Gavin Newsom (D) signed AB 1775, allowing marijuana businesses to offer non-cannabis food and non-alcoholic beverages and host live events such as concerts in their on-site cannabis consumption areas if they get permission from their local government. The new law officially took effect last January, but it has taken months for local officials in San Francisco and other cities to begin enacting their own ordinances to lay out the rules for how cannabis cafes can operate. Under the San Francisco proposal, a business would need to obtain a new Cannabis Café Permit as well as a Cannabis Consumption Permit. Businesses would need to implement written procedures “designed to discourage customers from removing cannabis products intended for on-site consumption from the designated consumption area” or the overall premises. There would be some restrictions on the name of cannabis cafes, barring those that would be likely to “mislead members of the public into believing cannabis products may legally be sold to persons under 21 years of age” or that would entice minors to attempt to patronize the businesses. Dispensaries would need to maintain accommodations for medical cannabis patients, which may include providing an area where the can communication confidentially with employees and maintaining an adequate supply of medical marijuana products. Written comments on the proposed cannabis cafe rules can be sent by email to officeofcannabis@sfgov.org or via mail or in person to Office of Cannabis; 49 South Van Ness; Suite 660; San Francisco, CA 94103. City officials separately released proposed rules changes to incorporate cannabis cafes into the existing Good Neighbor Policy for marijuana businesses. They also posted new resources for businesses to check their eligibility to open a cannabis cafe, as well as bulletin and a FAQ on the issue. Prior to signing the current cannabis cafe law, Newsom vetoed a prior version of the bill, saying that while he appreciated that the intent was to “provide cannabis retailers with increased business opportunities and an avenue to attract new customers,” he felt “concerned this bill could undermine California’s long-standing smoke-free workplace protections.” To that end, the measure as enacted contains changes to create separation between public consumption spaces and back rooms of businesses where food is prepared or stored in order to better protect the health of workers in line with the governor’s concerns. The law makes explicitly clear that hemp-based food items or drinks are not considered “non-cannabis” products that could be sold at the cafes. It also says that non-cannabis items “shall be stored and displayed separately and distinctly from all cannabis and cannabis products present on the premises.” The legislation also allows live musical or other performances on the premises of a cannabis retailer in areas where on-site consumption is allowed. Ahead of the governor’s signing of the measure, actor Woody Harrelson—who owns a marijuana lounge in West Hollywood called The Woods, alongside co-founders comedian Bill Maher and tennis star John McEnroe—called for its enactment. Whoopi Goldberg also joined in that push, with a video encouraging the governor to sign it. Earlier this month, Newsom announced that legal marijuana sales have generated nearly $8.4 billion in tax revenue for California communities since voters approved adult-use legalization in 2016. He also recently signed legislation to more clearly define the types of marijuana packaging and labeling that is prohibited due to appealing to children. The governor recently took credit for helping to lead the push for the state to legalize marijuana and discussed his own limited experience with using cannabis. Last October, however, he vetoed a bill that would have allowed certain marijuana microbusinesses to ship medical cannabis products directly to patients via common carriers like FedEx and UPS, stating that the proposal “would be burdensome and overly complex to administer.” Newsom did sign a bill earlier that month aimed at streamlining research on marijuana and psychedelics. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Last September, the governor also signed a measure into law to put a pause on a recently enacted tax hike on marijuana products. Meanwhile, a lawmaker spoke to Marijuana Moment about her decision to put her own bill to legalize cannabis dispensary drive-thru windows on hold for now. California’s treasurer recently said the marijuana legalization law that voters approved a decade ago has been a “complete failure” and should be replaced with a new ballot initiative that prioritizes consumers and small businesses. Republican gubernatorial candidate Steve Hilton, who is endorsed by President Donald Trump, recently told Marijuana Moment that taxes and regulations on cannabis are “too high.” The post San Francisco Officials Propose Rules For Cannabis Cafes Where People Could Consume While Listening To Live Music And Ordering Food appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A political action committee that shares the same treasurer as President Donald Trump’s own super PAC is using money raised from marijuana business donations to launch a series of ads for 11 vulnerable Republican members of Congress—including several who have voted against legislation to legalize cannabis. As Marijuana Moment recently reported, some of the U.S.’s largest cannabis companies donated a collective $11.5 million to America First Agriculture Action Inc. in June. The contributions—from Trulieve Inc., Curaleaf Inc., Verano Holdings LLC and Ascend Wellness Holdings Inc., along with other entities tied to Green Thumb Industries and AYR Wellness Inc.—brought the total amount of donations from cannabis businesses or an industry-linked political action committee to Trump-linked PACs to at least $15.05 million, according to a review of Federal Election Commission filings. Now, the agriculture-focused PAC is spending nearly $1.8 million of that to support several GOP lawmakers who are in tough reelection fights in November. The ads tout the voting records of Reps. Tom Barrett (R-MI), Nick Begich (R-AK), Rob Bresnahan (R-PA), Juan Ciscomani (R-AZ), Gabe Evans (R-CO), Brian Fitzpatrick (R-PA), Jen Kiggans (R-VA), Mike Lawler (R-NY), Scott Perry (R-PA), Bryan Steil (R-WI) and Derrick Van Orden (R-WI)—but they don’t mention marijuana at all. Instead, the spots targeted to each candidate note, for example, that they voted to ban insider trading by members of Congress and supported tax cuts, including a measure to make it so there would be no taxes on tips, overtime and social security. While most of the members featured in the new ads were first sworn into Congress in 2023 or 2025 and have no cannabis-related voting record, Fitzpatrick, Perry and Steil, have been around longer, beginning in 2017, 2013 and 2019, respectively. In 2020 and 2022, all three voted against Democratic-led bills to federally legalize marijuana. Kiggans, for her part, was a Virginia state senator prior to joining Congress and in that capacity voted against legislation to legalize cannabis. Ciscomani reportedly cheered the defeat of a marijuana legalization ballot initiative in Arizona in 2016, calling it an “awesome victory for our community.” Lawler said last year that it would be “wrong” for the Trump administration to reschedule cannabis, claiming that “marijuana is a gateway drug” and arguing that “most of the people [who] end up using harder substances start out on marijuana.” He also joined a sign-on letter to the president arguing that rescheduling cannabis would “send the wrong message to America’s children, enable drug cartels, and make our roads more dangerous.” The congressman is additionally a cosponsor of a bill that would continue to block marijuana businesses from taking federal tax deductions under Internal Revenue Service (IRS) code 280E, even under rescheduling. Perry backed an amendment to protect state medical cannabis programs from federal interference in 2015 as well as a separate proposal to shield recreational marijuana laws as well—but then voted against similar broad amendments in 2019 and 2020. Fitzpatrick and Steil also voted against the amendments to block federal interference with state marijuana laws. Fitzpatrick opposed amendments in 2014, 2015 and 2016 to let military veterans receive medical marijuana recommendations from Department of Veterans Affairs Doctors. Perry opposed that first iteration of the proposal before supporting it in the latter two votes. Both Fitzpatrick and Perry voted in support of legislation to increase cannabis businesses’ access to banking services in 2019 and 2021, however. The new marijuana-contribution-funded ad expenditures were first reported by Puck News, although that outlet questionably characterized the ads as a “reward” for most of the lawmakers voting to support recent spending legislation that included a provision to delay the effective date of the federal recriminalization of hemp THC products. In fact, some of the state-licensed cannabis businesses whose money is being used to pay for the ads see hemp products as competition and support efforts to rein in that industry. Additionally, there was no standalone vote on the hemp ban delay provision itself, so it’s difficult to characterize supporting or opposing the overall spending legislation as taking a position on any cannabis-related issue. Puck also did not note that the PAC took out an ad to support Begich while reporting the ads for the other lawmakers. Although Trump’s administration has taken steps to federally reschedule marijuana, Republican congressional leadership and many members of the party’s House and Senate conferences remain openly hostile to cannabis reform. The GOP-controlled House Appropriations Committee this year voted to block federal officials from taking further steps to carry out cannabis rescheduling, for example. House Majority Leader Steve Scalise (R-LA) told Marijuana Moment in an interview this month that he thinks “marijuana is a gateway drug, and it causes other problems down the road” for people who use it. In contrast, House Minority Leader Hakeem Jeffries (D-NY), who would be poised to become speaker next year if Democrats win back a majority in the chamber in November’s elections, said earlier this year that his party will “be in a position to do something about” marijuana laws “in the next Congress.” The only two times that Congress has considered marijuana legalization legislation on the floor was under Democratic control in 2020 and 2022, via the bills that Fitzpatrick, Perry and all but a handful of Republicans voted against. Notably, the treasurer of the agriculture PAC behind the new ads, Charles Gantt, is the same person named as treasurer of Trump’s political committee, MAGA Inc., which has separately received $2.05 million in donations from a cannabis-industry-backed committee, the American Rights and Reform PAC, Inc. Last year, that cannabis industry PAC additionally gave a total of $1.5 million to the agriculture PAC. Earlier FEC records also previously showed that Trulieve and Curaleaf contributed a total of $1 million to support Trump’s inaugural committee following his election in 2024. Curaleaf executive Matt Harrell is listed as treasurer of the American Rights and Reform PAC. The latest contributions from the cannabis companies to the Trump-linked agriculture PAC came weeks after the Department of Justice announced it is moving forward with the process of federally rescheduling marijuana, a reform that Trump backed during the 2024 campaign and then issued an executive order on late last year. Under an action announced by Attorney General Todd Blanche in April, marijuana products regulated by a state medical cannabis license immediately moved from Schedule I of the Controlled Substances Act (CSA) to Schedule III, as did any marijuana products that are approved by the Food and Drug Administration (FDA). A hearing is considering broader cannabis rescheduling, including for recreational products. Last August, America First Agriculture Action Inc. released an ad highlighting Trump’s endorsement of the reform on the campaign trail. “Under President Trump, America is back. Trump’s delivered the largest tax cut in history—putting more money in our pockets and restored America’s economic dominance,” the ad, which is being targeted at multiple zip codes throughout Washington, D.C., says. “Promises made, promises kept.” “Now it’s time to fulfill another promise from President Trump and reschedule cannabis, which supports over 400,000 jobs and creates billions of dollars in economic growth,” the PAC’s ad says. “Reschedule cannabis and stack another win, Mr. President.” Shortly after Trump signed his cannabis executive order in December, the similarly named nonprofit America First Agriculture Inc. released an ad applauding the move, arguing that it will “destroy” the illicit market and support seniors and military veterans who could benefit from cannabis. “Trump delivered a secure border, unleashed American energy and provided the largest tax cut in American history. Now Trump has delivered again by rescheduling cannabis, which was classified as more dangerous than fentanyl,” it said. “Trump’s action will destroy the cartel’s illicit black market, expand medical research and ensure seniors and veterans safely receive the care they need,” the ad continued. “Thank President Trump for delivering on another America First promise.” The cannabis industry-backed American Rights and Reform PAC separately released ads in May that attacked the marijuana policy record of President Joe Biden, whose administration initiated the cannabis rescheduling process that is now underway, in an apparent attempt to push Trump to go further on the issue. The Trump administration’s marijuana rescheduling move is also challenged by opponents through litigation. The post Trump-Linked PAC Uses Marijuana Business Donations To Campaign For GOP Lawmakers—Including Some Who Voted Against Legalization appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The U.S. House of Representatives is expected to vote on a bill this week to require the Department of Health and Human Services (HHS) to study how prevalent drug testing for marijuana, fentanyl and other drugs is in hospital emergency departments. The legislation, which cleared the House Energy and Commerce Committee in a unanimous 46-0 vote in July, is set to be taken up on the floor as soon as Tuesday, according to a schedule posted by the office of Majority Leader Steve Scalise (R-LA). The measure will be considered under a procedure known as suspension of the rules, which does not allow for amendments and requires a two-thirds supermajority for passage. The bill from Rep. Ted Lieu (D-CA) is known as “Tyler’s Law,” after Tyler Shamash, a 19-year-old who died following a fentanyl ingestion in 2018 and was not tested for the drug when brought to the hospital for a suspected overdose. While the legislation, H.R. 2004, is largely focused on fentanyl, it says that within a year of passage the HHS secretary would need to complete a study to determine “how frequently hospital emergency departments test for fentanyl (in addition to testing for other substances such as amphetamines, phencyclidine, cocaine, opiates, and marijuana) when a patient is experiencing an overdose.” The study would also need to look at costs associated with fentanyl testing, the potential benefits and risks of such testing and how it may impact patients’ experiences—including with respect to confidentiality and privacy protections and the patient-physician relationship. The bill, which has 65 House cosponsors, says that within six months of completing the study, HHS would also need to issue guidance covering: “(1) Whether hospital emergency departments should implement fentanyl testing as a routine procedure for patients experiencing an overdose. (2) How hospitals can ensure that clinicians in their hospital emergency departments are aware of which substances are being tested for in their routinely-administered drug tests, regardless of whether those tests screen for fentanyl. (3) How the administration of fentanyl testing in hospital emergency departments may affect the future risk of overdose and general health outcomes.” “A simple drug test can mean the difference between life and death,” Lieu said in a press release when the legislation was approved in committee. “Tyler’s Law is a bipartisan and commonsense piece of legislation. It is a privilege to work with Tyler’s mom, Juli, to honor Tyler’s memory and fight so no other family is forced to undergo such devastating loss.” — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Companion legislation in the Senate from Sen. Jim Banks (R-IN) was approved by the Health, Education, Labor, and Pensions Committee in January—but not before being amended to remove the language that references marijuana and other drugs besides fentanyl. Unlike the House bill, the HHS secretary would have three years to complete the study on hospital drug testing under the amended Senate proposal. In April, a pair of Republican senators filed a separate bill that would require the federal government to track the cost of hospitalization due to marijuana use. The Marijuana Impact on Medicaid Act of 2026 from Sens. Ted Budd (R-NC) and Pete Ricketts (R-NE) would require the secretary of the Department of Health and Human Services (HHS) to compile data on “Federal and State expenditures under the Medicaid program…that are attributable to costs incurred for providing medical assistance for inpatient hospital services, outpatient hospital services, and for services received at a hospital emergency room…related to marijuana use.” The bill’s language is similar to two amendments Budd previously filed on the cannabis and hospitalization issue that didn’t end up being considered on the Senate floor. The post Bill Directing Federal Health Officials To Track Testing For Marijuana And Other Drugs In Hospital ERs Set For House Vote This Week appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Medical marijuana appears to help cancer patients by decreasing pain, nausea, vomiting, anxiety and depression while also improving sleep, according to a new study conducted by government officials in Minnesota. The research, published on Friday by the Minnesota Office of Cannabis Management (OCM), is “one of the largest studies ever involving medical cannabis treatment,” officials said. It involved an analysis of marijuana purchases, self-evaluation surveys and symptom and side-effect ratings for 6,621 patients enrolled in the state’s medical cannabis program. Patients rated the severity of various symptoms when they first enrolled in the program and then again at various points while they were receiving treatment. Of the 82 percent of cancer patients who reported moderate to severe pain, nearly a third (30 percent) saw a reduction in their pain score of at least 30 percent within four months of their first medical marijuana purchase. More than half were able to maintain that level of reduced pain after an additional four months. Upon enrollment in the program, over half of participants said they experienced nausea and more than a quarter reported vomiting. Of those, after four months, forty percent reported a reduction in nausea scores of 30 percent or more, and 47 percent reported reduced vomiting scores of 30 percent or more. Those improvements lasted for at least another four months for 65 percent of those with nausea and 74 percent of those with vomiting. “These results show great promise in using cannabis for treating the symptoms that occur with cancer and cancer-related treatments,” Dr. Grace Christensen, a senior research analyst with OCM, said in a press release. “Even minor relief can improve patients’ quality of life and help them better manage battling the disease.” Among patients who experienced lack of appetite, 38 percent reported a 30 percent or greater improvement in scores within four months of their first medical cannabis purchase. Nearly two-thirds of those (63 percent) maintained that improvement for at least another four months. “Patients reported decreased nausea, vomiting, anxiety, and depression scores within four months of starting medical cannabis. Patients reported improved sleep scores within four months of starting medical cannabis.” The study also found benefits for patients with anxiety, depression, sleep and fatigue issues. “A majority of patients qualified for cancer-related conditions also reported moderate to severe scores for anxiety (71.7%), depression (60.5%), disturbed sleep (82.8%), and fatigue (91.5%),” it said. “Among patients with moderate to severe scores, 20.2% with anxiety, 22.4% with depression, 18.2% with disturbed sleep, and 10.8% with fatigue were able to achieve and maintain ≥30% reduction in symptom score.” The paper published by OCM also includes a number of quotes from individual patients about how medical cannabis helps them: “Improves my quality of life immensely. Helps with pain, has a calming effect on my anxiety improves my moods when the clouds of cancer return. I have Stage IV terminal cancer; but I’m relatively happy!” “Relief from pain, neuropathy, and help with sleep at night.” “Much less anxious and able to deal with things so much easier, it helps a lot with pain so I don’t have to take as much other stuff, it really helps with falling asleep and staying asleep longer.” “Lessening degree of pain, increase desire to eat.” “Most useful medication that I have for nausea, anxiety (since prognosis worsened).” “Help with appetite, nausea, and peace of mind and motivation.” Only 15 percent of patients participating in the study reported an adverse side effect of medical cannabis use, and 60 percent of those were described as mild. “Cannabis treatment appears relatively safe, and we now have strong observational evidence that many patients report better control of several cancer-related symptoms,” Dr. Dylan Zylla, oncologist and medical director of the HealthPartners Cancer Research Center, said. “I recommend starting with a low dose of THC and adjusting up gradually every few days to reduce the risk of side effects.” OCM Executive Director Eric Taubel said the study provided “encouraging results for people who are battling cancer.” A previous study published by state officials in Minnesota found that medical marijuana use by chronic pain patients is associated with significant improvements in life enjoyment, general activity and physical wellbeing. OCM also conducted a study showing that medical cannabis provides significant benefits for people struggling with sleep apnea. When it comes to cancer, the new OCM research is the latest to show that medical marijuana can provide relief for people struggling with the disease. For example, a recent federally funded study found that “cannabis use conferred therapeutic benefits for several health issues commonly encountered by cancer patients“—including “pain relief, improved sleep, physical relaxation, emotional regulation, and reduction of concomitant medication.” A separate study found that nearly one in five cancer survivors say they’ve used CBD after getting their diagnosis—primarily to manage pain, sleep difficulties and emotional distress. And more than half of those who used it for specific symptoms reported at least some benefit. Another recent study determined that medical marijuana extracts “meaningfully” improve cancer-related symptoms such as sleep difficulties and anxiety—though responses varied among patients depending on personal preferences for individual cannabinoid content of the extracts. Researchers separately found that components of marijuana show “consistent and statistically significant anti-tumor effects” in certain types of cancer, including glioblastoma and breast cancer. The study also showed that cannabinoids seem to “enhance chemotherapy efficacy.” Another systemic review concluded that studies “consistently show” that the CBD is a potential “anticancer agent across different cancer types”—and that effect applies to dogs as well as humans. A similar analysis showed that CBD “holds substantial promise as an anti-tumor agent” in addition to its other anti-inflammatory properties. Scientists explored CBD’s effect on many types of cancer—including some of the most aggressive ones, such as glioblastoma, which affects the brain. They also noted it can help suppressing the growth and metastasis of other cancers, including breast, lung, colorectal, ovarian and prostate, among others. In 2025, a paper published in the journal Pharmacology & Therapeutics, assessed a range of clinical and preclinical findings that the efficacy of chemotherapy drugs can be enhanced by medical marijuana. In a sign of greater acceptance of medical applications of cannabis, President Donald Trump’s choice to serve as the next White House drug czar has called medical marijuana a “fantastic” treatment option for seriously ill patients and said she doesn’t object to legalization, even if she might not personally agree with the policy. Also last year, a study found that “patients with cancer using cannabis report significant improvements in cancer-related symptoms.” The post Medical Marijuana Helps Cancer Patients With Pain, Anxiety And Nausea, Government Study Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Food and Drug Administration (FDA) officials are laying out the agency’s “new framework” for psychedelic medicines, including steps they are taking to “make psychedelic therapies available to patients more quickly, as warranted by the nation’s mental health crisis.” “The ongoing mental health crisis in the United States continues to worsen,” four FDA staffers wrote in a piece published in the New England Journal of Medicine (NEJM) last week. The agency “recognizes that although some people benefit from available treatment options, for others our current medications are not enough.” “One potential avenue for the development of better treatments includes psychedelic compounds,” they said, noting that substances such as psilocybin and DMT “have been used in traditional healing and spiritual practices since long before the advent of modern psychiatry.” While there has been a “prolonged period of quiescence” in the development of psychedelic medicines for decades, “due to research restrictions,” there has recently been a “dramatic resurgence of interest in psychedelic-based treatment for mental illness and substance use disorders” as a result of “advances in neurobiology and shifting social discourse.” In July, FDA published guidance to help researchers studying the therapeutic benefits of psychedelics navigate the “unique challenges” of such investigations. That is part of an “evolving” approach to integrate psychedelics into existing regulatory frameworks for therapeutic drugs, the agency staffers said in the new NEJM piece. “The guidance builds on the agency’s experience with drug development programs and incorporates relevant input from the scientific and patient community to address the distinct methodologic challenges in psychedelic clinical trial design—particularly issues around blinding, selection of control, and assessment of the durability of treatment effects.” The publication of the NEJM piece on psychedelics comes as FDA is hosting a hearing on the issue on Monday at which agency officials will hear testimony from dozens of advocates, researchers and industry participants. The article noted that preliminary research has indicated “favorable efficacy and safety outcomes” for psychedelics in treating “a number of psychiatric disorders.” As such, the agency has granted “breakthrough therapy” status to several substances, which allows for more intensive guidance from FDA officials as well as rolling and priority review for drug applications. One ongoing issue in psychedelics research, the FDA officials said, is functional unblinding—when participants in trials can easily tell whether that have received a substance that is being test like psilocybin or have instead received a placebo. The agency is “open to considering comparators other than inert placebo that may help to maintain blinding,” the article said. A recently published study found that high doses of THC from marijuana “can produce psychedelic-like states,” with the authors of that paper noting that it could potentially be useful as a comparator substances in future psychedelic research. The new FDA article in NEJM said that the agency is “prepared to consider innovative approaches to trial design, including the choice of comparator. “Although placebo-controlled studies raise the issue of functional unblinding and may complicate determinations of efficacy, the FDA may still expect such a study. Comparison with inactive placebo in at least one trial can help determine whether adverse events stem from the investigational drug or from other causes (such as underlying psychiatric or medical conditions). As always, close discussion with FDA staff is advisable.” The agency officials laid out steps that they said could “compress the overall drug-development-to-approval timeline and make psychedelic therapies available to patients more quickly, as warranted by the nation’s mental health crisis.” That includes combining rolling review and priority review with granting initial approvals “based on evidence of efficacy over a clinically meaningful duration (e.g., 12 weeks), in conjunction with a longer-term preliminary assessment of the need for and safety of treatment with additional doses (e.g., continuing blinded follow-up for 12 months),” they said, adding that issues related to optimal interval between doses and continued efficacy of treatment with additional doses “may be addressed in the post-marketing period.” FDA, they said, may require a Risk Evaluation and Mitigation Strategy (REMS) for psychedelics, additional post-marketing studies or both. “Given the growing demand and expanding evidence base, if psychedelics are approved, it will be imperative to establish gold-standard clinical practices for psychedelic-assisted therapy,” they wrote. “This includes rigorous training for providers, standardized dosing and monitoring protocols, and integration of FDA-approved treatments into care pathways. As such, the medical and regulatory communities must come together to ensure a framework for psychedelic treatments to be delivered safely, ethically, and effectively.” Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. said in a podcast released last week that he believes there will be an “enormous demand” for psychedelic therapies as they become legally available, and he thinks President Donald Trump is unique among his predecessors in championing the issue. The secretary also cited an executive order that Trump signed earlier this year to streamline research and access into psychedelic medicine. FDA and HHS in April announced steps that they say will help with “accelerating” therapeutic access to psychedelics for patients dealing with serious mental health conditions. Last month, the Substance Abuse and Mental Health Services Administration issued a report on recent advances in psychedelic medicine, along with recommendations for state policymakers on how to prepare for formal approval of drugs like psilocybin and MDMA. It also noted how the Schedule I status of many psychedelics has hampered scientific studies on their effects for decades. HHS and VA recently announced a partnership to collaborate on research and development of psychedelic medicines to treat people struggling with serious mental health conditions. Previously, FDA and HHS in April announced steps that they say will help with “accelerating” therapeutic access to psychedelics for patients dealing with serious mental health conditions. In May, a bipartisan coalition of 32 members of Congress sent a letter urging FDA to expedite ongoing reviews of psychedelic therapies. Lawmakers recently filed a new bill that would require the Department of Defense (DOD) to evaluate how ongoing research on the therapeutic benefits of psilocybin could help members of the military. A separate recently introduced bipartisan measure is intended to codify Trump’s psychedelics executive order into law. An amendment adopted as part of the National Defense Authorization Act would extend a psychedelics research effort at DOD for an additional six years. Photo elements courtesy of carlosemmaskype and Apollo. The post FDA Officials Lay Out Plan To Make Psychedelic Therapies Available To Patients ‘More Quickly’ appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

This is my first time i visit here. I found so many interesting stuff in your blog especially its discussion. From the tons of comments on your articles, I guess I am not the only one having all the enjoyment here keep up the good work alexistogel

RFK cites “enormous demand” for psychedelics; NE Supreme Court medical marijuana ruling; MA anti-cannabis ballot op-ed; MO hemp Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Your good deed for the day: donate to an independent publisher like Marijuana Moment and ensure that as many voters as possible have access to the most in-depth cannabis reporting out there. Support our work at https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW A medical cannabis business owner told Marijuana Moment she is planning to fight a decision by the Drug Enforcement Administration that she says could force her to fire two good employees if she wants to register for federal protections in line with the Trump administration’s move to federally reschedule marijuana. Health and Human Services Secretary Robert F. Kennedy Jr. said there will be an “enormous demand” for psychedelic therapies as they become legally available—praising President Donald Trump for being unique among his predecessors in championing the issue. “I can’t picture any other president in American history who would have done what he did. He turned on a dime. He got it in his head that this was something that he wanted to do.” Steve Reilly of the multi-state cannabis company Insa argues in a new Marijuana Moment op-ed that if Massachusetts voters approve a ballot initiative to roll back legalization, “consumers will continue to seek cannabis through other channels.” “None of the alternatives will produce the safe and regulatory tested products, jobs and tax revenue the current legal market generates.” The Nebraska Supreme Court rejected another attempt to overturn the state’s voter-approved medical cannabis law, ruling that a former state senator doesn’t have standing to bring a challenge. A Missouri representative who sponsored recently approved hemp product restrictions said lawmakers will have to address the issue again next session if Congress enacts federal rules for THC drinks. A marijuana dispensary in Ohio closed amid reports from two customers about “serious adverse health effects” after using vape pens they bought there. A spokesman for the county coroner said a person died at a nearby ER within days of the dispensary’s shutdown, but it’s not known if the death is related to products sold there. / FEDERAL The Drug Enforcement Administration Museum opened an exhibit about the 25th anniversary of 9/11. The U.S. Court of Appeals for the Sixth Circuit ruled that marijuana business contracts are unenforceable in federal court. / STATES Maryland Gov. Wes Moore (D) issued an executive order on workplace policies for government employees who are in recovery from substance use disorders. New York Gov. Kathy Hochul’s (D) deputy secretary for gaming, cannabis and alcohol suggested that officials may crack down on sales of THC drinks in grocery stores and other retail outlets. Here’s a look at where Wisconsin gubernatorial candidates stand on marijuana and hemp issues. Vermont’s lieutenant governor reached a settlement with regulators for allegedly growing at least 100 cannabis plants in a location where he did not have permission to do so. Colorado regulators sent a health and safety advisory about marijuana products with yeast, mold and aspergillus above acceptable limits. They also adopted changes to various cannabis rules. Rhode Island regulators published guidance on changes to federal hemp laws. Missouri regulators are accepting applications to serve on the Cannabis Regulation Collaborative. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / LOCAL Houston, Texas’s mayor blamed the district attorney for a spike in marijuana arrests. A New York City councilmember coauthored an op-ed about his bill to allow regulators to block licenses for the smoke shops that illegally sell marijuana. / INTERNATIONAL Mexico’s Supreme Court ruled authorized recreational cannabis self-consumption can include preparing infused foods. / SCIENCE & HEALTH A study found that “CBD suppresses glioma growth and limits invasion.” / ADVOCACY, OPINION & ANALYSIS The Republican National Convention featured a speech from Ross Ulbricht—who President Donald Trump freed from prison after being convicted for running the Silk Road online drug market—in which he said the president “opened the door to medicine the government had criminalized for half a century.” The president of the California Statewide Law Enforcement Association said marijuana tax revenue hauls highlight the need for enforcement against illegal operators. / BUSINESS Definium Therapeutics, Inc. announced that the Food and Drug Administration granted Breakthrough Therapy status to its formulation of LSD. Sunnyside Dispensary workers in Chillicothe, Ohio voted to unionize. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: Photo courtesy of Kimberly Lawson. The post DEA pressures medical cannabis business over workers with convictions (Newsletter: September 14, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Booked High Class Delhi Escort for car sex highway. Drove to a lonely road at night. Fucked in backseat rough. Cars passed with headlights on. The adrenaline was high and exciting. Almost caught by police patrol. Escaped just in time fast. Best risky sex ever. Will try forest next.

Hey what a brilliant post I have come across and believe me I have been searching out for this similar kind of post for past a week and hardly came across this. Thank you very much and will look for more postings from you. alexistogel login

This is super cool! It always makes me think about how many amazing, hidden gems are out there, just waiting to be discovered. Sometimes, you stumble upon the best places in the most unexpected ways, whether it's through a friend's recommendation or even a random chat. It's kind of like how you might meet someone fascinating on a platform like Omegle – you never know who you'll connect with or what cool insights they might have. Finding unique venues is definitely a treasure hunt, and I bet there are tons of people out there with perfect suggestions!

This is my first visit to your web journal! We are a group of volunteers and new activities in the same specialty. Website gave us helpful data to work. ไซด์ไลน์

“We had a death in Holzer Medical Center ER in that time frame… We have no report yet on the cause of death. We don’t know if it’s related or not.” By Jake Zuckerman, Signal Cleveland This story was originally published by Signal Cleveland. Sign up for their free newsletters at SignalCleveland.org/subscribe. A marijuana dispensary in Southeast Ohio closed after two customers reported what have only been described as “serious adverse health effects” after using a vape pen they bought there. The Herbal Wellness Center, a Vext Sciences dispensary in Jackson, on Friday said it voluntarily closed shop at the request of the Ohio Division of Cannabis Control (DCC). “At this time, the Company is not aware of any substantiated evidence establishing that any Vext product caused or contributed to either reported medical event,” the company said. Neither the state nor the company have been willing to describe the two health events or answer whether anyone is reported to have died. A spokesman for the county coroner said a person died at a nearby ER within five or six days of the dispensary’s shutdown, but it’s unknown whether the death is related to any product sold there. Scott Everett, the company’s general counsel, said in an interview Wednesday the company’s Vapen branded cartridge products are on a “precautionary hold” pending a laboratory review. He said all products undergo testing at independent, state licensed labs before they’re sold. “Out of respect for the individuals involved and the ongoing review that [regulators are] doing, we’re not commenting on health related matters or specific products,” he said. DCC spokesman Tom Brockman said follow-up testing on a sample taken from the same product lot as one purchased by a patient who experienced adverse health effects detected no harmful contaminants. He said that some products have been put on hold from sales or transfer to other stores while additional testing continues. He said follow-up testing was conducted at the regulators’ request at an independent lab, funded by Vext. No contaminants have been detected. The DCC has declined to provide any information on the nature of the health events or specifics about the product at issue. “Because this is an ongoing investigation and the product in question has not shown to be contaminated via initial or follow-up testing, the Division is not disclosing any health-related information or specific product details,” Brockman said. When asked if any fatalities occurred, Brockman referred inquiries to local law enforcement. Buster Hall, an investigator with the county coroner’s office, said someone died within five or six days of the dispensary’s closure, and it’s too soon to draw conclusions. “We had a death in Holzer Medical Center ER in that time frame,” he said. “We sent the body for an autopsy. We have no report yet on the cause of death. We don’t know if it’s related or not.” While health departments are typically responsible for run-of-the-mill food safety investigations, state officials license, oversee and investigate the legal marijuana industry in Ohio. County Health Commissioner Kevin Aston said he had no comment. “The health department does not inspect nor keep any kind of records on this facility, and my department and I have not been involved with this investigation,” he said. Vext Sciences, which runs dispensaries in Ohio and Arizona, owns the Herbal Wellness Center. It operates four other locations in Ohio, all of which remain open. Signal Cleveland is a nonprofit news organization covering local government, education, health, economy and public safety. The post Ohio Marijuana Dispensary Closes Amid Reports Of ‘Adverse Health Effects’ In People Who Bought Vapes appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Struggling to turn a rough idea into a usable prompt for ChatGPT or Midjourney? Prompt Gen generates copy-ready prompts by scene and target platform, and the no-signup trial makes it easy to test before committing.

“If they make a change in the drinks, then this is something we will have to look at in January…putting a framework around specifically the drinks.” By Rebecca Rivas, Missouri Independent When Joshua Grigaitis founded the Mighty Kind Company in St. Louis in 2019, his team started by producing flavored sparkling water infused with CBD, a non-intoxicating compound found in cannabis. The company has since become a major player in the market for intoxicating hemp-THC beverages. But with a federal ban looming, Grigaitis said he is prepared to return to the company’s roots. The ban is now set to take effect December 11, after President Donald Trump signed a bill last week delaying its implementation by one month. “Big picture is we’re gonna sell a variety of products, and we’re gonna stay diversified,” Grigaitis said. “We were originally a CBD company. We’ve never had the thought: we’re not going to have anything to do if we can’t sell THC drinks. We’ll just do something else.” Hemp companies across Missouri and the nation are rethinking their business plans in anticipation of the ban. While Grigaitis is confident Mighty Kind can adapt through new products, companies built around low-dose, full-spectrum cannabis products—those created specifically for people seeking relief from chronic pain or health ailments—could face a far more difficult path forward. Dr. Ethan Russo, a neurologist in Washington and founder of the medical cannabis research and drug development company Credo Science, said the medical side of the industry is in “chaos.” “There are just many, many companies going out of business, some of whom have produced very good products that have been helpful to people with medical conditions that haven’t had relief otherwise,” Russo said. “It’s a very bad time for the industry.” Russo said these products focus on the therapeutic compounds found in cannabis, such as CBD and CGB, and the small amount of THC, such as 3 mg or less, in them activates those non-intoxicating compounds and makes them more effective. While Congress may end up allowing and regulating these products, particularly considering Trump’s support for them, there is no wiggle room in the legislation Missouri lawmakers passed this spring. When Missouri’s law goes into effect on November 12, intoxicating hemp products will be “put under the purview of the department’s existing regulations for cannabis products,” said Lisa Cox, spokeswoman for the Missouri Department Health and Senior Services, which oversees the state’s cannabis program. On November 12, everything that comes from cannabis and is intoxicating—or has more than 0.4 milligrams of THC per container—will be considered marijuana and can only be sold in licensed dispensaries. The cannabis also has to be grown and manufactured in licensed Missouri facilities. For now, beverages will stay on store shelves until December 11, and there will be no other regulation of these items except that people now must be 21 to buy them until then. Missourians won’t be able to purchase hemp-derived THC products online after November 12, even though it’d be federally still legal. There are currently a few low-dose full-spectrum products available in dispensaries. Dr. Patricia Hurford, a physical medicine and rehabilitation specialist in Chesterfield, said she anticipates she’ll hear more concern from her patients when their full-spectrum products are no longer available in November. Like Russo, Hurford commends Missouri’s legislation for protecting children and regulating the quality of cannabis products, but she worries about access to medicinal products. “Patients require protection,” Hurford said, “and sometimes protecting those patients means we have to take dangerous products off the shelf. Sometimes it just means we’re offering and preserving access to safer and lower-dose alternatives.” Hemp vs marijuana This wave of complicated, confusing policymaking around cannabis is pushing a necessary conversation about having two different laws for hemp and marijuana, Russo said. That conversation should be, “legalize it and regulate it. That’s the only way that this can work,” he said. Hemp and marijuana are essentially terms the government uses to distinguish between the part of the cannabis plant that has high amounts of THC. Hemp has previously been defined as any part of the plant containing 0.3 percent or less delta-9 THC by dry weight. Last November, a provision in the federal spending bill amended the definition of hemp, changing the limit to a total THC concentration of less than .3 percent on a dry weight basis, rather than only delta-9 THC. It also prohibits products from containing more than 0.4 milligrams of THC per container. Missouri’s law was aimed at getting unregulated intoxicating cannabis products, particularly those that are attractive to children, off the shelves. Republican state Rep. Dave Hinman of O’Fallon, who sponsored the ban, believes the state will send out communication directly to retailers to make sure they understand the nuisance of the law. Hinman anticipates Missouri’s upcoming legislative session to be filled with much more work to be done on this issue, and he said he’s been asked by state leaders to continue taking the lead on cannabis-related legislation. If Congress allows full-spectrum products, Missouri will have to approve that use through a bill. And if there is further delay of the federal ban, then lawmakers will have to pass regulations on beverages. “If they make a change in the drinks, then this is something we will have to look at in January…putting a framework around specifically the drinks,” Hinman said. “If we need to make changes and adjustments, I will absolutely be involved in this.” Panic for patients Hurford said the marijuana industry was born out of creating medicinal, therapeutic products. However, now dispensaries are often more focused on recreational products, she said, and offer an environment that might be intimidating for patients to enter and find what they need. “Let’s get back to promoting the medicinal aspects in those products,” she said. Healer is an example of a company that has helped her patients, and she believes its co-founder, Dr. Dustin Sulak, is a “well-respected, knowledgeable clinician.” But its products will be banned in November, and company owners say they won’t pursue trying to work within the marijuana regulations. Healer’s co-founder and CEO, Brad Feuer, said marijuana cultivation facilities nationwide focus on growing cannabis with high THC and low CBD content, which doesn’t work with their formula. And secondly, it wouldn’t be cost effective for the company or patients. Katherine Golden is a nurse who seven years ago founded an independent cannabinoid health hotline called Leaf411. She said while more medicinal products with only one or two milligrams of THC were available in dispensaries when her hotline first started, many of them have been pulled off the shelves. “That to me is the heartbreak of what’s happening with our legislation because you’re taking access away from a product that is not being abused,” Golden said. “The hemp market—those who are the responsible players—are providing this product that the retailers aren’t carrying because it doesn’t sell enough for them.” Part of the reason is because these customers need it delivered to their homes, particularly those caring for people with dementia or those struggling with ailments, she said. Her hotline has already gotten a taste of the panic patients may feel in November after California’s ban was put in place in July. “I can only guess when we see another state like Missouri ban on Nov. 12, we’re going to hear from Missourians calling us saying, ‘What do I do? I just found this out,’” she said. “Because a lot of patients are so involved in what they’re doing in their lives, they’re not following what’s happening.” Andrew Mullins, executive director of the Missouri Cannabis Trade Association that represents the state’s marijuana businesses, said for patients to be protected, their medical products must be “tested, taxed, age-gated and responsibly packaged, which simply isn’t happening with intoxicating hemp.” “Many dispensaries already carry low-dose THC products,” Mullins said, “and we expect there will be more emphasis on medicinal uses of their products and development of additional products to meet patient demand, as online and unregulated channels diminish.” Adrian Holguin, a California-based cannabis consultant under his business CannaShark, said Missouri’s regulatory framework ties the hands and potential profits of businesses working in intoxicating hemp and low-dose, full-spectrum. Like Healer, most of these businesses will choose to not to find a place in Missouri’s market. “They have to take their operations and either leave the state and find the last remaining states,” he said, “or they have to be ready to pivot in a direction that’s going to make sense and that follows the legislation that’s coming.” Business owners could try to work with a licensed Missouri marijuana manufacturer or cultivator to make their products under the new law. However, even for marijuana companies, Missouri is “a tough state to crack,” he said, partly due to the consolidation of facility licenses. Other states are going to be more accommodating. “When you decide on business,” he said, “where to play is one of the main questions you ask yourself.” Grigaitis believes this moment is going to produce challenges, but it’s also going to push innovation. Mighty Kind is looking to launch a new seltzer with Lion’s Mane mushroom concentration, he said, which promotes relaxation, focus and brain support. “I see it as all very positive,” Grigaitis said, “you know, evolution of moving from alcohol to something less harmful for everybody and plant magic of all kinds.” This story was first published by Missouri Independent. The post Missouri Moves Ahead With Hemp THC Product Restrictions As Federal Ban Is Delayed, But May Reassess In 2027 appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

This is my first visit to your web journal! We are a group of volunteers and new activities in the same specialty. Website gave us helpful data to work. editoto.ink

That is really nice to hear. thank you for the update and good luck. portaltaurino.com

Our commitment is to your complete happiness and deep satisfaction. Find Escort Service Laxmi Nagar for an adventure that feels both daring and safe. Our companions offer physical elegance and intimate conversation that captivates your soul. We create a fantasy atmosphere where pleasure is paramount, and every touch promises an orgasmic journey.

This is my first visit to your web journal! We are a group of volunteers and new activities in the same specialty. Website gave us helpful data to work. koi toto

Our Escort in Connaught Place are more than just companions—they are artists of pleasure, ready to fulfill your every desire. Each encounter is a unique journey tailored to your preferences for maximum satisfaction.

“If licensed adult-use retailers disappear, consumers will continue to seek cannabis through other channels… None of the alternatives will produce the safe and regulatory tested products, jobs and tax revenue the current legal market generates.” By Steve Reilly, Insa If you are a Massachusetts voter who has not been following the debate over cannabis policy, Question 8 on this November’s ballot deserves your attention. The measure asks voters whether Massachusetts should repeal the laws that allow and regulate adult-use cannabis sales. The implications go well beyond whether a dispensary remains open. The question reaches the system of licensed businesses, product testing, taxation and regulatory oversight that Massachusetts has built over the past decade—seeking to eliminate 27,000 jobs and $300,000,000 in tax revenue that will need to be made up somewhere else. Understanding what is actually being proposed and what would replace the current system is essential before casting a ballot. Massachusetts voters approved adult-use marijuana legalization in 2016. Since then, the commonwealth has developed a regulated market overseen by the Cannabis Control Commission (CCC), with licensed cultivators, manufacturers, retailers and testing laboratories operating under regulated state rules. Although there have been documented issues with regulatory oversight, the legislature recently took action to make improvements, and the ballot question could ultimately undermine that progress rather than build on it. Question 8—formally titled “An Act to Restore a Sensible Marijuana Policy”—would repeal the state laws governing the possession, distribution, cultivation and taxation of adult-use marijuana. While the medical market would remain legal and adults 21 and older would still be permitted to possess up to one ounce without civil or criminal penalties, possession of more than one ounce and up to two ounces would carry a civil penalty. The effect would be to penalize possession over an ounce, while keeping lesser amounts fully legal but eliminating the commercial dispensaries where product can be purchased. The practical effect will be to sow confusion and chaos with regards to what cannabis you can possess and where you can obtain it, likely pushing consumers into the illicit market. This is intentional by those brining the initiative who hope to diminish public support. A “yes” vote is not simply a vote to change cannabis regulations or impose new restrictions on dispensaries. It would eliminate the existing adult-use retail system. So what does that mean for consumers? Today, an adult-use consumer can enter a licensed Massachusetts cannabis retailer and purchase products that are subject to state requirements for testing, labeling, packaging, security and business oversight. The regulated system also establishes rules around who can sell cannabis and where it can be sold. If Question 8 passes, that licensed adult-use retail structure would go away, giving way to an unregulated market where these products continue to be legal to possess and use. The practical question for consumers is not whether cannabis possession remains legal, rather it is whether Massachusetts will continue providing a commercially regulated, licensed place for adults to purchase cannabis products. That raises important public-safety questions. There is also an economic consequence. Since legalization, Massachusetts’s adult-use cannabis market has generated more than $10 billion in cumulative sales, including approximately $1.65 billion in 2025 alone. In 2025, the cannabis industry generated approximately $308 million in state revenue and another $51 million in local-option tax revenue for municipalities that supports cultivation and manufacturing employees, laboratory workers, security companies, construction and real estate businesses, technology providers, professional services and other vendors. Eliminating the adult-use licensing and taxation framework would fundamentally alter the businesses and public revenues that have developed around it. One of the central arguments for legalization was that a regulated marketplace could provide adults with an alternative to an illicit market. But if licensed adult-use retailers disappear, consumers will continue to seek cannabis through other channels. Whether that means medical dispensaries, personal cultivation, transfers between adults or illicit sellers will depend on how the market responds. None of the alternatives will produce the safe and regulatory tested products, jobs and tax revenue the current legal market generates. As a registered voter, the choice on Question 8 is consequential. Question 8 represents a decision between maintaining a regulated adult-use marketplace that has existed for nearly a decade and moving Massachusetts toward a different model in which marijuana remains legal but unregulated. As voters consider the question, they should look beyond campaign slogans and understand exactly what the initiative would change, what protections would remain, what would disappear and how those changes could affect consumers, communities, employees and businesses. Cannabis policy should ultimately be about public safety, responsible access, accountability and informed consumer choice, not an unregulated free-for-all market. Whatever position a voter takes on Question 8, that decision should begin with a clear understanding of what is actually on the ballot. More information is available at at stoptherepealma.com. Steve Reilly is head of government relations for Insa, a cannabis company that operates in Massachusetts and other states. The post What Massachusetts Cannabis Consumers Need to Know About Question 8, The Ballot Measure To Roll Back Legalization (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“Kuehn did not have either taxpayer standing or standing for a matter of great public concern to challenge the constitutionality of the acts.” By Zach Wendling, Nebraska Examiner The Nebraska Supreme Court on Friday decided a longtime medical cannabis opponent will not have another day in court to try to overturn the state’s voter-approved medical cannabis laws, at least for now. Chief Justice Jeffrey Funke, in a unanimous 29-page ruling, agreed with a lower court judge’s decision that former state Sen. John Kuehn of Heartwell did not have standing to challenge Nebraska’s medical cannabis laws. Kuehn argues that such state laws, including Nebraska’s voter-enacted legalization of medical cannabis, are “preempted” by federal law under the U.S. Constitution’s supremacy clause defining marijuana as a more dangerous drug that states are precluded from regulating. “We conclude that Kuehn did not have either taxpayer standing or standing for a matter of great public concern to challenge the constitutionality of the acts,” Funke wrote. “We therefore affirm the district court’s order dismissing Kuehn’s operative complaint without prejudice.” “Without prejudice” means Kuehn could bring a similar case in the future if circumstances change. For instance, since June 2025, the Nebraska Legislature has appropriated more funds to the Nebraska Medical Cannabis Commission and passed new legislation around cannabis. What is ‘standing’? For a case to proceed, a litigant must prove they’ve suffered an “injury in fact” by the time a case is filed or later amended. Kuehn filed his case in December 2024 and last amended it June 2025. Kuehn conceded he had not yet suffered the direct injury but sought to use exceptions. “Standing refers to whether a party had, at the commencement of the litigation, a personal stake in the outcome of the litigation that would warrant a court’s exercise of its subject matter jurisdiction and remedial powers on that party’s behalf,” Funke explained in the opinion. Lancaster County District Judge Susan Strong dismissed Kuehn’s case on June 26, 2025. She also presided over and ruled against a preelection challenge from Kuehn, filed in September 2024. The Supreme Court last week affirmed Strong’s ruling on the validity of Nebraska’s medical cannabis laws, also in a unanimous ruling from Funke. Shifting federal guidance During oral arguments in April in Kuehn’s preemption appeal, no attorneys or justices asked about shifting federal guidelines on marijuana. U.S. Attorney General Todd Blanche federally downgraded state-licensed medical cannabis to a Schedule III drug in April, down from a Schedule I drug. Schedule I drugs, such as heroin, LSD, ecstasy and peyote, are drugs the federal government has classified as having a high likelihood of abuse and no currently accepted medical value. Schedule III drugs are defined as those with moderate to low potential for physical and psychological dependence, such as Tylenol with codeine, ketamine and testosterone. Nebraska’s Medical Cannabis Commission is working toward implementing a state-licensed program and has licensed four cultivators. Nebraska Gov. Jim Pillen (R) and Attorney General Mike Hilgers (R) signed off on a first set of regulations for the commission this summer. The commission is rewriting its regulations to add fees before moving to license product manufacturers or dispensaries. The Legislature authorized the commission to do so this year. Access to legally purchase medicine in Nebraska is still months, if not at least a year, away. Standing exceptions Kuehn tried to use two “narrow” exceptions to the standing rule: that he should be able to sue to try to prevent an “illegal expenditure” of public funds (taxpayer standing) or because the laws constitute a “matter of great public concern” (“great public concern standing”). “It is not enough to wait for the United States government to one day come to Nebraska and challenge these acts,” Kuehn’s attorney Eddie Greim of Missouri had told the justices. “Instead, Nebraska’s courts should be open to Nebraskans who want to hold their Nebraska state government to its constitutional limitations.” Funke wrote that other jurisdictions might find Kuehn had taxpayer standing, such as in other states, but Funke said doing so for Nebraska would be “inconsistent with our jurisprudence.” Funke also wrote that Kuehn’s claims did not present the “rare” circumstances to justify an exception for great public concern. Unlike in other taxpayer standing cases that try to block public spending alone, Kuehn sought to go further and declare the Nebraska medical cannabis laws unconstitutional. Had the case proceeded and later returned to the Supreme Court, it would take five justices to declare the laws unconstitutional. For standing, Kuehn needed a simple majority, or four judges. AG’s Office: Others could sue Zachary Pohlman, the state deputy solicitor general defending five state officials from Kuehn’s lawsuit, had argued that at least five parties would be better suited to sue than Kuehn, such as the federal government, Hilgers, a property owner, a prospective medical cannabis user or a criminal defendant charged with illegally possessing cannabis asserting the laws as a defense. The Supreme Court ruled that its finding whether Kuehn lacked standing was not related to whether others could sue in Kuehn’s place. Pillen was named in the suit, as were Secretary of State Bob Evnen, Department of Health and Human Services CEO Steve Corsi, former State Treasurer Tom Briese and Tax Commissioner Jim Kamm. Kuehn had also sued the 2024 ballot sponsors behind the voter-approved laws and current and former members of the Medical Cannabis Commission. The Nebraska Attorney General’s Office had threatened to sue the state Medical Cannabis Commission if it issued licenses. But no such challenge materialized when the commission licensed the first cultivators in October 2025. No other state lawsuits have been filed at this time. Hilgers’s office has joined a federal lawsuit seeking to challenge the DOJ’s rescheduling of marijuana, which President Donald Trump is calling for. In an unsigned statement Friday, Nebraskans for Medical Marijuana said another “desperate lawsuit, designed to erase the will of Nebraska voters and destroy medical cannabis, has failed.” “For nearly two years, people with powerful political connections and deep pockets have thrown everything they can at us,” the statement said. “Lawsuits, accusations, obstruction and delay, because they refuse to accept what 71 percent of Nebraskans overwhelmingly decided.” The group, which led the 2024 effort to legalize and regulate medical cannabis, said no matter the money, influence or political power behind the “next attack,” it won’t erase that vote. The next Medical Cannabis Commission meeting is Monday. This story was first published by Nebraska Examiner. Photo courtesy of Mike Latimer. The post Nebraska Supreme Court Rejects Another Challenge To Voter-Approved Medical Marijuana Law appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I really like your take on the issue. I now have a clear idea on what this matter is all about.. toto

Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. believes there will be an “enormous demand” for psychedelic therapies as they become legally available, and he thinks President Donald Trump is unique among his predecessors in championing the issue. The secretary was speaking on the latest episode of a podcast he hosts for HHS in which he interviewed Bryan Hubbard, the CEO of Americans for Ibogaine. “One of the challenges that we will also face in the federal government [is] there’s going to be a demand for it,” Kennedy said of psychedelics. “If we do get it to the point where where it becomes available for veterans, there’s going to be an enormous demand for it and you need for every veteran treated approximately more than 100 hours of support staff. So there’s an expense attached to it.” The secretary also cited an executive order that Trump signed earlier this year to streamline research and access into psychedelic medicine. “I can’t picture any other president in American history who would have done what he did. He turned on a dime,” Kennedy said. “He got it in his head that this was something that he wanted to do.” “He talked to some of the veterans who you met in the Oval Office during the executive order signing. And Joe Rogan introduced him to some of those veterans and he just became convinced,” he said, referring to the popular podcaster who texted the president about psychedelics just days before he decided to sign the order. “I think he broke down a lot of barriers in doing that.” The president’s move “opens up all kinds of possibilities or and pathways for evidence-based research into psychedelics,” Kennedy said. Kennedy, who once said he had a “wonderful experience” on LSD while trying to see dinosaurs as a teenager, said he thinks that “most Americans” view psychedelics with a kind of negative bias. “This was hippie stuff from back in the 60s and that it was recreational,” he said of their view. “And it’s not really kind of a legitimate therapeutic treatment.” The secretary admitted that he himself is surprised to hear stories of people taking ibogaine once and changing their lives without having to use it again. “It’s hard for me to believe that you can do something once and…that you can then live off the laurels of that kind of spiritual realignment, that you don’t have to do something you know renew it on a daily basis,” he said. Could psychedelics change the way we treat opioid addiction?@w_bryan_hubbard has spent years fighting the opioid crisis and advocating for rigorous research into psychedelic medicine. On #TheSecretaryKennedyPodcast, we discuss ibogaine, addiction, veterans, the promise and… — Secretary Kennedy (@SecKennedy) September 10, 2026 Kennedy said earlier this year that the Trump administration is “very anxious” to create a pathway for access to psychedelics therapy and that top officials across federal agencies want to “get it out to the public as quickly as possible.” In an interview on the Joe Rogan Experience in February, Kennedy said he’s confident “we’re going to get it done,” with plans to develop and finalize rules that would enable patients with conditions such as post-traumatic stress disorder (PTSD) and depression to access psychedelic substances like psilocybin and MDMA in a “very controlled setting.” “Everybody in my agency…is very anxious to get a rule out there that will allow these kind of studies and will allow access under therapeutic settings, particularly [for] the military soldiers who have suffered these injuries to get access to these products,” the HHS secretary said. “We’re working through that process now. We’re all working on it and trying to make it happen.” “I think that we’re going to get it done,” he said. President Trump opened a new chapter in psychedelic medicine by creating pathways for rigorous, evidence-based research into these promising therapies. On the latest episode of #TheSecretaryKennedyPodcast, @w_bryan_hubbard and I discuss what this moment could mean for the future… pic.twitter.com/oC2HnzT1zp — Secretary Kennedy (@SecKennedy) September 10, 2026 Last June, Kennedy said his agency is “absolutely committed” to expanding research on the benefits of psychedelic therapy and, alongside of the head of FDA, is aiming to provide legal access to such substances for military veterans “within 12 months.” Veterans Affairs Secretary Doug Collins also disclosed in April that he had an “eye-opening” talk with Kennedy about the therapeutic potential of psychedelic medicine. And he said he’s open to the idea of having the government provide vouchers to cover the costs of psychedelic therapy for veterans who receive services outside of VA as Congress considers pathways for access. Last month, the Substance Abuse and Mental Health Services Administration issued a report on recent advances in psychedelic medicine, along with recommendations for state policymakers on how to prepare for formal approval of drugs like psilocybin and MDMA. It also noted how the Schedule I status of many psychedelics has hampered scientific studies on their effects for decades. HHS and VA recently announced a partnership to collaborate on research and development of psychedelic medicines to treat people struggling with serious mental health conditions. Separately, the Food and Drug Administration (FDA) issued finalized guidance to help researchers studying the therapeutic benefits of psychedelics navigate the “unique challenges” of such investigations. The agency also announced it will be holding a public hearing on psychedelic therapy issues in September. Previously, FDA and HHS in April announced steps that they say will help with “accelerating” therapeutic access to psychedelics for patients dealing with serious mental health conditions. In May, a bipartisan coalition of 32 members of Congress sent a letter urging FDA to expedite ongoing reviews of psychedelic therapies. Lawmakers recently filed a new bill that would require the Department of Defense (DOD) to evaluate how ongoing research on the therapeutic benefits of psilocybin could help members of the military. A separate recently introduced bipartisan measure is intended to codify Trump’s psychedelics executive order into law. An amendment adopted as part of the National Defense Authorization Act would extend a psychedelics research effort at DOD for an additional six years. The post There Will Be ‘Enormous Demand’ For Psychedelic Treatments, RFK Says, Praising Trump’s Action On The Issue appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

A medical marijuana dispensary owner in Mississippi is planning to fight a decision by the Drug Enforcement Administration (DEA) that she says could force her to fire two good employees if she wants to register for federal protections in line with the Trump administration’s move to federally reschedule cannabis. Nicole Huff, CEO of the Wildflower Medical Dispensary in Aberdeen, shared with Marijuana Moment correspondence that a DEA official sent about the two workers in question, who have past felony convictions. As a result of those criminal records, the business must either fire the employees, withdraw its application for federal protections, seek a waiver while becoming ineligible for expedited processing or go before an agency judge. “I am frustrated and disappointed that, after these two individuals have worked for me for more than a year without any issues or disciplinary actions, the DEA would require me to remove them from their positions,” Huff told Marijuana Moment. Ashlie Way, a diversion investigator with DEA’s Jackson District Office, sent Huff an email last Thursday saying that “because you have the 2 employees who have felony convictions, you have the following options when it comes to your application.” “You can waive your right to the expedited application in the event you want to proceed with an employment waiver,” it said. “Or you can withdraw your DEA application.” “If you choose not to do either of those, I will send your application up for what we call an Order to Show Cause. An Order to Show cause is when an application is sent to Headquarters. They will assign it to an attorney who will send out a letter to the applicant letting them know that they have the right to request a hearing. If they choose to have a hearing, the applicant will respond to the letter, and a hearing will be set for them before the Administrative Law Judge (ALJ). I believe the hearing is held in Washington DC. The applicant will then have the opportunity to present their case to the ALJ. From there, the Judge will determine if the application proceeds to a registration or if the application will be denied.” The email said the dispensary would need to make a decision by no later than the close of business four days later—on Monday, which was Labor Day. Huff told Marijuana Moment that she will take the issue before a DEA judge. “I plan to request employment waivers on their behalf,” she said. “I understand that doing so may require me to travel to Washington, D.C., and appear in federal court, and I am prepared to take the necessary steps.” “It is already extremely difficult for individuals with nonviolent felony convictions to obtain stable employment. I intend to ask the court to consider a grandfather provision for individuals who were employed before the DEA application was submitted,” Huff said. “If an employee has a nonviolent conviction, has maintained satisfactory employment and has received no disciplinary actions, I believe that person should be eligible for an exemption from mandatory removal.” The two Wildflower workers in question “have demonstrated their reliability through more than a year of successful employment,” she said. “I plan to ask that their individual circumstances and employment records be considered before a final decision is made. I hope other dispensary owners would do the same.” Huff didn’t directly respond to Marijuana Moment’s question about what kind of felony convictions her employees have. Marijuana Moment also reached out to DEA about the number of applications for registration it has received to date and how many of those are being similarly held up due to workers’ criminal records, but a representative did not respond. DEA regulations for registration to handle controlled substances state that “the registrant shall not employ, as an agent or employee who has access to controlled substances, any person who has been convicted of a felony offense relating to controlled substances.” The agency does, however, allow employers to submit requests for waivers. “A waiver will not be considered unless there are valid reasons to believe that diversion is unlikely to occur,” a DEA manual says. The agency will weigh several factors in making its determination on a waiver, it says: A detailed description of the nature and extent of the individual’s past controlled substances violations, including all pertinent documentation; Current status of the individual’s state licensure; Extent of individual’s proposed access to controlled substances. “Access” is not limited to only physical access to controlled substances, but includes any influence over the handling of controlled substances; Registrant’s proposed physical and professional safeguards to prevent diversion by the individual; Status of employing registrant regarding handling of controlled substances; Other pertinent information uncovered by DEA in its investigation of the individual’s or registrant’s handling of controlled substances; and All other relevant factors or materials. In Huff’s case, even if she asks for and receives a waiver, she will still have to waive her right to the agency’s expedited application process for registration for the federal benefits and protections that come with rescheduling, according to Way’s email. Meanwhile, the agency has been conducting inspections and follow up interviews with medical cannabis businesses that register for federal protections, but industry sources say the way the agency has been carrying out those activities varies between DEA’s regional offices throughout the country. In June, Mississippi medical cannabis businesses spoke to Marijuana Moment about being visited by DEA officials, who told them they were among the first in the country to be seen for inspection under the registration process. Last month, Marijuana Moment obtained a list of 26 questions that DEA officials are sending to medical cannabis businesses in Colorado as part of the consideration of their applications for registration. The questions on the form being sent to Colorado businesses include: Will you be ordering marijuana or marijuana products from other states? Will you be ordering synthetic cannabinoids? Will you be ordering marijuana seeds or plants in order to grow at the dispensary location? What are the specific types of products offered (e.g., gummies, extracts, concentrates, tinctures, topical products, oils, flower buds, oil cartridge vapes, dry herb vapes, pre-rolled cannabis cigarettes, etc.)? Please identify your medical marijuana supplier(s) to include name(s), address(es), and DEA registration number(s). Please provide a copy of any labeling, packaging, and sealing policies (refer to federal guidelines for medical marijuana packaging pursuant to Title 21 CFR § 1301.13(k)(8) which states that the label of all medical marijuana products shall, when dispensed to or for a patient, contain a clear, concise warning that it is a crime to transfer the drug to any person other than the patient). How is defective (e.g. mold, rot, bug infestation), expired, or discontinued/deadstock marijuana products disposed of? The agency launched its initial registration form for dispensaries in April, days after Attorney General Todd Blanche issued an order immediately moving marijuana products regulated by a state medical cannabis license from Schedule I of the Controlled Substances Act (CSA) to Schedule III, along with marijuana products that are approved by the Food and Drug Administration (FDA). A DEA hearing that recently concluded testimony is considering broader marijuana rescheduling. Meanwhile, the agency said it plans to launch new forms for additional types of state-licensed medical marijuana businesses beyond dispensaries, such as manufacturers, distributors and laboratories. The currently available registration form for state-licensed medical marijuana dispensaries asks for information about their processes for storage, ordering, dispensing, inventory, maintenance of records and other aspects of their businesses. The application asks about specific details about security measures such as vaults, safes, secure storage rooms, access controls, alarm systems and on-site security personnel. Applicants can choose whether they are requesting to handle marijuana, marijuana extracts or naturally derived delta-9 THC. While only medical marijuana is currently being moved to Schedule III, the application also asks potential registrants whether their firms handle or dispense recreational marijuana. The DEA application also asks businesses to submit information about their state cannabis licenses and to answer questions about criminal and disciplinary histories. It also asks: “Has anyone who will be involved in the ownership or operation of the firm previously manufactured, distributed, and/or dispensed any controlled substance without a DEA registration authorizing such activity?” Presumably, every currently operational state-legal cannabis business has key personnel who have done so, since medical marijuana was, until recently, a Schedule I controlled substance that DEA did not broadly authorize manufacturing, distribution and dispensation of. Applicants must additionally list suppliers from which they intend to procure marijuana, and to disclose whether they anticipate repackaging or relabeling cannabis products. They also need to provide lists of individuals with the business that are anticipated to have “access to controlled substances,” including their dates of birth, social security numbers, criminal histories related to drugs. Photo courtesy of Mike Latimer. The post Marijuana Dispensary Owner Says DEA Is Forcing Her To Fire Workers In Order To Get Federal Protections Under Trump’s Rescheduling Move appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

We introduce you to beautiful, a lovely, curvaceous young Escorts in Dwarka who takes great pleasure in meeting her clients' requirements and realizing their most ambitious dreams. She is well appreciated for her remarkable attractiveness and outstanding customer service.